The efficacy and safety of Salvia officinalis combined with statin have not been evaluated in dyslipidemic diabetes mellitus type 2 (DDMT2) so far. The plant extract antioxidant activity was determined by the DPPH radical scavenging assay. The total flavonoid, total phenolic and quercetin contents of the capsules containing the plant extract were also measured. Moreover, the effects of 2-month extract intake (500 mg capsule three times a day) as add-on to daily use of 15 mg glyburide, 2000 mg metformin and 10 mg atorvastatin on the blood levels of fasting glucose (FG), 2 h postprandial glucose (2hPPG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride, high-density lipoprotein cholesterol (HDL-C), serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), creatinine and body mass index were studied in 50 patients and compared with the placebo group (n=50).The extract IC 50 in the DPPH assay was 87.26±0.003 µg/mL (mean±SD), whereas the ascorbic acid IC 50 was 5.626± 0.001 µg/mL (mean±SD). The total flavonoid, total phenolic and quercetin contents of the capsule containing the plant extract were 39.76±3.58 mg of rutin equivalents (mean±SD), 30.33±1.23 mg of gallic acid (mean±SD) and 0.13 mg, respectively. The extract lowered FG, 2hPPG, HbA1c, TC, LDL-C and triglyceride levels, but increased HDL-C level compared to the placebo at the endpoint (P<0.05). The extract did not affect the other parameters significantly and no adverse effect was reported. The extract has substantial antioxidant activity which may be beneficial for the prevention of the cardiovascular complications of DDMT2. Moreover, addition of the extract to statin therapy is apparently safe and further improves lipid profile. (24), the radical scavenging activity of the extract was also studied. Moreover, the extract was standardized by determination of the total flavonoid, total phenolic, and quercetin contents.
useful in the treatment of dyslipidemia and diabetes mellitus type 2 (9) . Agonists of PPAR γ prevent atherosclerotic CVD (10) . Salvia officinalis L.
(sage) (Lamiaceae family) leaves are used widely as a food flavoring. Moreover, infusion of 4-6 g of dry sage leaves in two divided doses per day is taken in the traditional medicine as an antihyperglycemic agent to treat diabetes mellitus (11) . Sage consists of volatile oils, tannins, diterpenes, triterpenes, steroids, flavones and flavonoids (12) (13) (14) . Sage leaf extracts (constituents) have demonstrated a variety of pharmacological effects such as in vitro agonistic action on the PPAR γ (12, 13) , in vitro α-glucosidase and pancreatic lipase inhibition, and lipid absorption inhibitory and antihypertriglyceridemic effects in mice (14, 15) , antioxidant and lipid peroxidation inhibitory effects in rat brain and liver homogenates in vitro (16) , anti-inflammatory effect in rat hind paw acute inflammation induced with oil of turpentine (17) , antihyperglycemic effect in streptozocin-induced diabetic rats (18) , insulin sensitizer and gluconeogenesis inhibitory effects in primary cultures of hepatocytes from healthy sagetea-drinking rats (metformin-like effects) (19) .
There have been few clinical trials on the antihyperglycemic and antidyslipidemic effects of sage (20) (21) (22) (23) . Notably, the efficacy and safety of sage combined with statin therapy to improve lipid profile have not been evaluated so far. Hence, the present study was undertaken. Since antioxidant property is clinically important for the prevention of the cardiovascular complications of DDMT2 (24), the radical scavenging activity of the extract was also studied. Moreover, the extract was standardized by determination of the total flavonoid, total phenolic, and quercetin contents.
Materials and methods

Preparation of the extract and placebo capsules
Sage was collected and extracted, and the extract and placebo capsules were prepared as described previously (22) . The sage capsules contained 500 mg of the extract powder. The placebo capsules contained toast powder. The sage and placebo capsules were identical in appearance.
The extract DPPH assay
Inhibition of diphenyl-2-picrylhydrazyl (DPPH) radicals by the extract was assayed according to a method described previously (25) . A mixture consisting of an extract solution at different concentrations (1.5 mL) and the methanolic solution of the DPPH reagent (1.5 mL) was prepared in a volumetric flask. The mixture was left to stand for 30 min in a dark place, and then the absorption was measured at 517 nm using a spectrophotometer (Human, USA). The radical scavenging activity (RSA) was calculated as a percentage of DPPH discoloration using the equation: RSA (%)= (Ac-As/Ac)×100 where Ac is the absorbance of the negative control and As is the absorbance of the plant sample or ascorbic acid.
Ascorbic acid was used as reference standard. The assay results were expressed as IC50 denoting the antioxidant concentration which reduces the DPPH radicals about 50%.
Determination of the extract total phenolic content
The total phenolic contents were determined through the Folin-Ciocalteu colorimetric method described previously (26) . In brief, the plant extract solution (1mL) was mixed with 500 µL of the Folin-Ciocalteu reagent and 5 mL distilled water in a volumetric flask. After 5 min, 1 mL of 15% sodium carbonate solution was added to the mixture and then kept in the dark for 30 min, after which the absorbance was determined at 725 nm using a spectrophotometer (Human, USA). Gallic acid was used to generate the standard curve, and the reduction of the Folin-Ciocalteu reagent by the samples was expressed as mg of gallic acid equivalents per capsule.
Determination of the total flavonoid content
The total flavonoid content was determined by a modified method described previously (27) . The extract (1 mg/mL) or standard was mixed with 4 mL of distilled water and 300 µL of a 5% sodium nitrite solution and after 5 min, 300 µL of 10% aluminum chloride solution was added to the mixture. After 6 min, 2 mL of 1 M sodium hydroxide and 3 mL of distilled water were added to the mixture. The solution was properly mixed and absorbance was measured at 510 nm using a spectrophotometer (Human, USA). Rutin (100 µg/mL up to 1200 µg/mL) was used to construct the standard curve and the results were expressed as mg of rutin equivalents per capsule.
Determination of the extract quercetin content
Quercetin was measured by the HPLC method described previously (28) . The chromatographic separations were achieved using a YMC 
Results
Phytochemical analysis of the extract
The IC 50 of the extract was 87.26± 0.003 µg/mL (mean±SD), whereas the IC 50 of ascorbic acid was 5.626 ± 0.001 µg/mL (mean ± SD). The total flavonoid content as milligram rutin equivalent per capsule was 39. 
